Coalition of EU groups call for bold and open trade policy

18 October 2024

As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website.

First launched in July, the Coalition has grown into a group of 43 business associations, all of them united by the shared idea that trade openness is a key driver to keep the EU competitive, prosperous, and resilient in the face of global challenges. According to the Coalition, trade openness must therefore become a top priority and veritable leitmotiv for the EU over the next five years.

With one in every five jobs in the European Union (EU) relying on exports, trade openness is a key driver of economic growth and job creation. Trade helps to attract foreign investments, fosters growth and innovation in the EU, and also benefits consumers by increasing product choice. Importantly, trade diversification in sourcing and exports also enhances resilience, thus helping the EU to weather and overcome future crises. The message from the Open Trade Coalition to the incoming Commission is therefore loud and clear: an ambitious open trade must become a top priority and leitmotiv over the next five years to keep Europe competitive, prosperous, and resilient on the world stage.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical